Dr. Tyler James Willenbrink, MD

Dr. Willenbrink practices at Zitelli & Brodland Surgery Center in Pittsburgh, Pennsylvania.

Dr. Willenbrink's NPI, 1306367396, was assigned on June 29, 2017. Dr. Willenbrink graduated from University of South Carolina School of Medicine in 2017. Dr. Willenbrink holds Pennsylvania license MD473646.

Dr. Willenbrink's primary practice is Zitelli & Brodland Surgery Center, at 5200 Centre Avenue Suite 303, Pittsburgh, PA 15232. The practice phone is (412) 681-9400.

Dr. Willenbrink's primary practice is Zitelli & Brodland Surgery Center in Pittsburgh, Pennsylvania. The medical group on file is Zitelli, Brodland & Lim. Dmand AI also links Dr. Willenbrink to 1 more group practice or clinic, named with a free account. Dr. Willenbrink's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Willenbrink practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Willenbrink's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dmand AI has Dr. Willenbrink's licenses on file in 2 states: Pennsylvania and South Carolina.

CMS data shows 1,680 Medicare services from Dr. Willenbrink across 25 procedure codes in 2024, for 378 Medicare patients. Medicare paid $389,892 for them. Every service was in an office.

CMS counts 378 Medicare patients who saw Dr. Willenbrink in 2024. The largest group is 65 to 74, with 166 patients. 75% of them have high cholesterol, and 73% have high blood pressure. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Willenbrink's median patient age at 74, with 44% women.

In 2024, Dr. Willenbrink wrote 114 Medicare Part D claims for 83 patients. 97% of them were for generic drugs. CMS names the drug for 73 of them, across 4 drugs with 11 or more claims each, at $1,455 in total drug cost. In 2023, CMS named 99 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Willenbrink for performance year 2024, reported as part of a group. Dr. Willenbrink accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 46 procedures of melanoma (skin cancer) excision by Dr. Willenbrink, more than 86% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 14 papers to Dr. Willenbrink, published from 2020 to 2025. 2020 was the busiest year, with 3. The most frequent topics are Skin Neoplasms, Mohs Surgery and Carcinoma, Squamous Cell. Dr. Willenbrink has published most often in Cutis. Dr. Willenbrink's most frequent co-authors are David G. Brodland, MD, Joi B. Carter, MD and Anokhi Jambusaria-Pahlajani, MD.

CMS Open Payments shows 16 general payments to Dr. Willenbrink from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 87% of the total. VYNE Pharmaceuticals Inc. paid the most, $185.

Dr. Willenbrink graduated from University of South Carolina School of Medicine in 2017.